| 今开：11.49 | 昨收：11.28 |
| 最高：11.83 | 最低：11.1 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：6.87203166E8 |
薛定锷之猫07-18 22:27
$Phathom(PHAT)$ 2024-07-18 9:11am
FDA has approved Voquezna 10 mg tablets for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease or GERD in adults.
1、Non-Erosive GERD is the largest category of GERD and is characterized by reflux-rela...查看全文
泼天财富我自来07-17 14:13
$Phathom(PHAT)$ The FDA has set a target action date of July 19, 2024, for expanded approval of Voquenza, which would target the larger Non-Erosive GERD patient population.
FDA 最晚本周五19号确认是否批准新药，大家什么意见？查看全文
小海龟和大海龟07-23 16:29
7月18日，Phathom制药公司宣布，美国FDA已批准Voquezna(vonoprazan,沃诺拉赞)10毫克片剂用于缓解成人非糜烂性胃食管反流病(GERD)相关的胃灼热。
Vonoprazan是一种新型口服小分子钾竞争性酸阻滞剂(PCAB)，通过抑制质子泵的工作来减少胃酸的产生。
Vonoprazan代表了30多年来胃食管反流病治疗...查看全文
Phathom(PHAT)06-01 06:45
$Phathom(PHAT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-067548 Size: 5 KB 网页链接查看全文
Phathom(PHAT)06-07 02:05
$Phathom(PHAT)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-155898 Act: 34 Size: 318 KB 网页链接查看全文
Phathom(PHAT)05-25 07:55
$Phathom(PHAT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-064835 Size: 7 KB 网页链接查看全文
Phathom(PHAT)07-18 02:55
$Phathom(PHAT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-084182 Size: 5 KB 网页链接查看全文
Phathom(PHAT)05-25 07:45
$Phathom(PHAT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-064830 Size: 7 KB 网页链接查看全文
Phathom(PHAT)06-15 04:15
$Phathom(PHAT)$ 10-K/A [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-073629 Act: 34 Size: 9 MB 网页链接查看全文
Phathom(PHAT)05-25 04:05
$Phathom(PHAT)$ 8-K Current report, items 5.07 and 8.01 Accession Number: 0001193125-24-147017 Act: 34 Size: 157 KB 网页链接查看全文
小海龟和大海龟07-23 16:29
7月18日，Phathom制药公司宣布，美国FDA已批准Voquezna(vonoprazan,沃诺拉赞)10毫克片剂用于缓解成人非糜烂性胃食管反流病(GERD)相关的胃灼热。
Vonoprazan是一种新型口服小分子钾竞争性酸阻滞剂(PCAB)，通过抑制质子泵的工作来减少胃酸的产生。
Vonoprazan代表了30多年来胃食管反流病治疗...查看全文
薛定锷之猫07-18 22:27
$Phathom(PHAT)$ 2024-07-18 9:11am
FDA has approved Voquezna 10 mg tablets for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease or GERD in adults.
1、Non-Erosive GERD is the largest category of GERD and is characterized by reflux-rela...查看全文
泼天财富我自来07-17 14:13
$Phathom(PHAT)$ The FDA has set a target action date of July 19, 2024, for expanded approval of Voquenza, which would target the larger Non-Erosive GERD patient population.
FDA 最晚本周五19号确认是否批准新药，大家什么意见？查看全文
SeekingBiotech2023-12-06 23:37
PCAB
PHAT FDA accepts NDA for VOQUEZNA for the treatment of heartburn associated with Non-Erosive gastroesophageal reflux disease (GERD).
PDUFA 07/19/24$Phathom制药(PHAT)$查看全文
药明在线2023-05-27 20:59
近日，专注于开发和商业化针对胃肠道疾病和功能紊乱新疗法的生物医药公司Phathom Pharmaceuticals宣布向美国FDA重新提交伏诺拉生（vonoprazan）的新药申请（NDA），用于治疗糜烂性食管炎，也被称为糜烂性胃食管反流病（GERD）。新闻稿指出，如果获得批准，伏诺拉生将成为FDA批准的首个获批用于治疗...查看全文
SeekingBiotech2023-05-10 21:43
PHAT on track to resubmit erosive esophagitis (Erosive GERD) NDA this Q$武田制药(TAK)$ $Phathom制药(PHAT)$
PCAB查看全文
SeekingBiotech2023-04-04 21:38
$Phathom制药(PHAT)$ $武田制药(TAK)$
PHAT Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new drug application (NDA) this quarter
P-CAB查看全文
产业链观察2023-04-04 21:36
#药闻简讯# 2023年4月4日，专注于开发和商业化胃肠道疾病新疗法的生物制药公司$Phathom制药(PHAT)$ 今天在最近与FDA就Phathom的侵蚀性食管炎NDA和H.VOQUEZNA® TRIPLE PAK®和VOQUEZNA® DUAL PAK® NDAs的幽门螺杆菌批准后补充文件（PAS）。这两份CRL仅...查看全文
$Phathom制药(PHAT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001395064-21-000111 Size: 7 KB 网页链接
$Phathom制药(PHAT)$ 内部交易: 2021-06-08,10% Owner,TAKEDA PHARMACEUTICAL CO LTD ,卖出,100普通股, $35.00
$Phathom制药(PHAT)$ 内部交易: 2021-06-07,10% Owner,TAKEDA PHARMACEUTICAL CO LTD ,卖出,2264普通股, $35.05
$Phathom制药(PHAT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001395064-21-000109 Size: 6 KB 网页链接
$Phathom制药(PHAT)$ 8-K Current report, item 5.02 Accession Number: 0001193125-21-182893 Act: 34 Size: 17 KB 网页链接
$Phathom制药(PHAT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001395064-21-000107 Size: 5 KB 网页链接
$Phathom制药(PHAT)$ 内部交易: 2021-06-02,10% Owner,TAKEDA PHARMACEUTICAL CO LTD ,卖出,4300普通股, $35.18
$Phathom制药(PHAT)$ 内部交易: 2021-06-01,10% Owner,TAKEDA PHARMACEUTICAL CO LTD ,卖出,11211普通股, $35.78
$Phathom制药(PHAT)$ 内部交易: 2021-05-28,10% Owner,TAKEDA PHARMACEUTICAL CO LTD ,卖出,8905普通股, $36.19
$Phathom制药(PHAT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001395064-21-000105 Size: 12 KB 网页链接